Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Pituitary Today II

New Molecular, Physiological and Clinical Aspects

Editor(s): Arzt E. (Buenos Aires) 
Bronstein M. (São Paulo) 
Guitelman M. (Buenos Aires) 
Cover

Functional Role of the RET Dependence Receptor, GFRa Co-Receptors and Ligands in the Pituitary

Garcia-Lavandeira M. · Diaz-Rodriguez E. · Garcia-Rendueles M.E.R. · Rodrigues J.S. · Perez-Romero S. · Bravo S.B. · Alvarez C.V.

Author affiliations

Department of Physiology, School of Medicine, IDIS University of Santiago de Compostela (USC), Santiago de Compostela, Spain

Related Articles for ""

Arzt E, Bronstein M, Guitelman M (eds): Pituitary Today II: New Molecular, Physiological and Clinical Aspects. Front Horm Res. Basel, Karger, 2010, vol 38, pp 127–138

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: July 05, 2010
Cover Date: 2010

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9444-8 (Print)
eISBN: 978-3-8055-9445-5 (Online)

Abstract

The RET receptor is a tyrosine kinase receptor implicated in kidney and neural development. In the adenopituitary RET and the co-receptor GFRa1 are expressed exclusively in the somatotrophs secreting GH. RET is implicated in a clever pathway to maintain at physiological levels the number of somatotrophs and the GH production. Thus, in absence of its ligand GDNF, RET induces apoptosis through massive expression of Pit-1 leading to p53 accumulation. In the presence of the ligand GDNF, RET activates its tyrosine kinase and promotes survival at the expense of reducing Pit-1 expression and downregulating GH. Recent data suggest that RET can also have a second role in pituitary plasticity through a second co-receptor GFRa2.

© 2010 S. Karger AG, Basel


References

  1. Melmed S: Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-1618
  2. Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581-588
  3. Tahira T, Ishizaka Y, Sugimura T, Nagao M: Expression of proto-ret mRNA in embryonic and adult rat tissues. Biochem Biophys Res Commun 1988;153:1290-1295
  4. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H: Cloning and expression of the ret protooncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988;3:571-578
  5. Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M: Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 1990;5:97-102
  6. Takahashi M, Cooper GM: Ret Transforming Gene Encodes a Fusion Protein Homologous to Tyrosine Kinases. Mol Cell Biol 1987;7:1378-1385
  7. Jing S, Wen D, Yu Y, et al: GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 1996;85:1113-1124
  8. Treanor JJ, Goodman L, de Sauvage F, et al: Characterization of a multicomponent receptor for GDNF. Nature 1996;382:80-83
  9. Airaksinen MS, Saarma M: The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-394
  10. Santoro M, Carlomagno F, Melillo RM, Fusco A: Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 2004;61:2954-2964
  11. Pierotti MA, Santoro M, Jenkins RB, et al: Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992;89:1616-1620
  12. Bongarzone I, Butti MG, Coronelli S, et al: Frequent activation of ret proto-oncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994;54:2979-2985
  13. Arighi E, Popsueva A, Degl'Innocenti D, et al: Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol Endocrinol 2004;18:1004-1017
  14. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM: Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 2006;22:627-636
  15. Yoshimoto K, Tanaka C, Moritani M, et al: Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor (GDNF) genes in human pituitary adenomas. Endocr J 1999;46:199-207
  16. Urbano AG, Suarez-Penaranda JM, Dieguez C, Alvarez CV: GDNF and RET-gene expression in anterior pituitary-cell types. Endocrinology 2000;141:1893-1896
  17. Japon MA, Urbano AG, Saez C, et al: Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. J Clin Endocrinol Metab 2002;87:1879-1884
  18. Coya R, Alvarez CV, Perez F, Gianzo C, Dieguez C: Effects of TGF-betal on prolactin synthesis and secretion: an in-vitro study. J Neuroendocrinol 1999;11:351-360
  19. Canibano C, Rodriguez NL, Saez C, et al: The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J 2007;26:2015-2028
  20. Mehlen P, Thibert C: Dependence receptors: between life and death. Cell Mol Life Sci 2004;61:1854-1866
  21. Allouche M: ALK is a novel dependence receptor: potential implications in development and cancer. Cell Cycle 2007;6:1533-1538
  22. Bernet A, Fitamant J: Netrin-1 and its receptors in tumour growth promotion. Expert Opin Ther Targets 2008;12:995-1007
  23. Bordeaux MC, Forcet C, Granger L, et al: The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J 2000;19:4056-4063
  24. Majumder PK, Pandey P, Sun X, et al: Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem 2000;275:21793-21796
  25. Sun X, Wu F, Datta R, Kharbanda S, Kufe D: Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J Biol Chem 2000;275:7470-7473
  26. Liu H, Lu ZG, Miki Y, Yoshida K: Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol 2007;27:8480-8491
  27. Voss OH, Kim S, Wewers MD, Doseff AI: Regulation of monocyte apoptosis by the protein kinase Cdelta-dependent phosphorylation of caspase-3. J Biol Chem 2005;280:17371-17379
  28. Soto JL, Castrillo JL, Dominguez F, Dieguez C: Regulation of the pituitary-specific transcription factor GHF-1/Pit-1 messenger ribonucleic acid levels by growth hormone-secretagogues in rat anterior pituitary cells in monolayer culture. Endocrinology 1995;136:3863-3870
  29. Garcia A, Alvarez CV, Smith RG, Dieguez C: Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol 2001;15:1484-1495
  30. Lin FT, MacDougald OA, Diehl AM, Lane MD: A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci USA 1993;90:9606-9610
  31. Lin FT, Lane MD: CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc Natl Acad Sci USA 1994;91:8757-8761
  32. Wang ND, Finegold MJ, Bradley A, et al: Impaired energy homeostasis in C/EBP alpha knockout mice. Science 1995;269:1108-1112
  33. Flodby P, Barlow C, Kylefjord H, Ahrlund-Richter L, Xanthopoulos KG: Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. J Biol Chem 1996;271:24753-24760
  34. Schaufele F: CCAAT/enhancer-binding protein alpha activation of the rat growth hormone promoter in pituitary progenitor GHFT1-5 cells. J Biol Chem 1996;271:21484-21489
  35. Jacob KK, Stanley FM: CCAAT/enhancer-binding protein alpha is a physiological regulator of prolactin gene expression. Endocrinology 1999;140:4542-4550
  36. Day RN, Voss TC, Enwright JF, 3rd, Booker CF, Periasamy A, Schaufele F: Imaging the localized protein interactions between Pit-1 and the CCAAT/ enhancer binding protein alpha in the living pituitary cell nucleus. Mol Endocrinol 2003;17:333-345
  37. Enwright JF, 3rd, Kawecki-Crook MA, Voss TC, Schaufele F, Day RN: A PIT-1 homeodomain mutant blocks the intranuclear recruitment of the CCAAT/ enhancer binding protein alpha required for prolactin gene transcription. Mol Endocrinol 2003;17:209-222
  38. Schuchardt A, D’Agati V, Larsson-Blomberg L, Costantini F, Pachnis V: Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994;367:319-320
  39. Kashuk CS, Stone EA, Grice EA, et al: Phenotypegenotype correlation in Hirschsprung disease is illuminated by comparative analysis of the RET protein sequence. Proc Natl Acad Sci USA 2005;102:8949-8954
  40. Fisher S, Grice EA, Vinton RM, Bessling SL, McCallion AS: Conservation of RET regulatory function from human to zebrafish without sequence similarity. Science 2006;312:276-279
  41. Garcia-Lavandeira M, Quereda V, Flores I, et al: A GRFa2/Prop 1/stem (GPS) cell niche in the pituitary. PLoS ONE 2009;4:e4815
  42. Quereda V, Malumbres M: Cell cycle control of pituitary development and disease. J Mol Endocrinol 2009;42:75-86
  43. Bilodeau S, Roussel-Gervais A, Drouin J: Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells. Mol Cell Biol 2009;29:1895-1908

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: July 05, 2010
Cover Date: 2010

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9444-8 (Print)
eISBN: 978-3-8055-9445-5 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.